Peters W A, Andersen W A, Hopkins M P
Puget Sound Oncology Consortium, Seattle, WA.
Cancer. 1989 Mar 1;63(5):836-8. doi: 10.1002/1097-0142(19890301)63:5<836::aid-cncr2820630507>3.0.co;2-5.
Forty-six patients with measurable disease received chemotherapy for advanced primary or recurrent carcinoma of the fallopian tube. The response rate was 9% with single-agent therapy, 29% with multiagent therapy without cisplatin, and 81% with cisplatin-containing combination therapy. Survival was significantly improved in Stage III/IV with the addition of cisplatin-based combination therapy.